AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02717260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial random noise stimulation (tRNS) (Starstim)
Description: subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
Study NCT02717260 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial random noise stimulation (tRNS) (Starstim)
Description: subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
Study NCT01102907 — intervention group
Intervention type: OTHER
Intervention: Liquid Breakfast
Description: The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
Study NCT01102907 — intervention group
Intervention type: OTHER
Intervention: Solid Breakfast Meal
Description: The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
Study NCT04993222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome®
Description: IV infusion
Study NCT03350984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin
Description: NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL.
Study NCT03350984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine and Lispro insulin
Description: Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
Study NCT01341951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor
Description: 300 I.U twice daily for 5 days
Study NCT03332082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth positioner
Description: Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
Study NCT01203254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Colesevelam 625 mg tablet; 3 times daily 2 tablets
Study NCT01203254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet: 3 times daily 2 tablets
Study NCT04459767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: 80 mg subcutaneous injection
Study NCT04459767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT02568982 — intervention group
Intervention type: OTHER
Intervention: Exams and questionnaires
Description: Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
Study NCT03470974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-titration strategy
Description: The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
Study NCT02723578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
Study NCT02723578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg PO once daily on days 1-21 every 21 days
Study NCT03574324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF+CCRT
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
Study NCT03574324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CCRT+PF
Description: Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
Study NCT04173364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Injectable solution of ropivacaine 0.5%
Study NCT04173364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% Injectable Solution
Description: Dilution of ropivacaine to the concentration of 0.1%
Study NCT02172170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 single rising dose
Study NCT02172170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT03023046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03023046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03023046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03226873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Peer education, counseling, and facilitation of PrEP care
Study NCT01600742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
Study NCT01600742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.
Study NCT01221103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone, ofatumumab and bendamustine
Description: * Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)
Study NCT04455984 — intervention group
Intervention type: OTHER
Intervention: Date collection
Description: Retrospective data analysis
Study NCT03665415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NDGameSquad
Description: The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
Study NCT03665415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDGameSquad
Description: The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
Study NCT04243421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Soft tissue aesthetics, marginal bone level on CBCT
Study NCT01939990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo looks like the study drug but it does not contain active ingredients.
Study NCT01939990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5 to 10mg per day
Study NCT00393705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Biphasic Aspart 30/70
Description: Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
Study NCT00393705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro LM
Description: Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
Study NCT00393705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro MM
Description: Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
Study NCT00393705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro LM
Description: Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
Study NCT01455090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Study NCT00279422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: visilizumab
Study NCT02187874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed umbilical cord occlusion
Study NCT02187874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early umbilical cord occlusion
Study NCT02187874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT00279422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: visilizumab
Study NCT00402883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
Study NCT01583530 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose Group: Belimumab IV 240 mg
Description: Belimumab IV 240 mg administered on Day 0
Study NCT01583530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose Group: Belimumab SC 2 x 120 mg
Description: Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
Study NCT01583530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose Group: Belimumab SC 1 x 240 mg
Description: Belimumab SC 240 mg x 1 injection on Day 0
Study NCT01583530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose Group: Belimumab SC 1 x 200 mg
Description: Belimumab SC 200 mg x 1 injection on Day 0
Study NCT01583530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly
Description: Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
Study NCT01583530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
Description: Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
Study NCT04491396 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gentle Yoga and Yogic Breathing
Description: Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB.
Study NCT01859936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
Study NCT00772148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP -Tacro
Description: LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)
Study NCT00772148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)
Study NCT04046380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: work of breath measurement and calculation
Description: The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
Study NCT02187874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT01653405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted behavioral intervention
Description: The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
Study NCT03824028 — intervention group
Intervention type: DEVICE
Intervention: Clareon® IOL AutonoMe™ automated preloaded delivery system
Description: Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
Study NCT01680549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
Study NCT01680549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
Study NCT02547714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
Study NCT03361579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: c.p. intervention description
Study NCT03915522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single adductor canal block
Description: The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
Study NCT03915522 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated adductor canal block
Description: The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
Study NCT02990156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil Embolization System
Description: deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
Study NCT02990156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotrol device from Medronic
Description: Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
Study NCT01094639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling root planing
Description: Deep gum cleaning with local anesthesia
Study NCT01094639 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supragingival Prophylaxis
Description: Plaque removal
Study NCT00586729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vashe
Description: Antimicrobial irrigant
Study NCT00586729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mafenide acetate
Description: Antimicrobial solution
Study NCT01231308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y-Gastric Bypass
Description: Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
Study NCT01231308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle modification and Optimal medical Therapy
Description: Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
Study NCT05933070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INKmune
Description: INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.